Citius PharmaceuticalsCTXR
Market Cap: $99.1M
About: Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Employees: 22
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.3% less ownership
Funds ownership: 17.09% [Q1] → 16.79% (-0.3%) [Q2]
4% less funds holding
Funds holding: 73 [Q1] → 70 (-3) [Q2]
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
27% less capital invested
Capital invested by funds: $24.4M [Q1] → $17.7M (-$6.69M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
EF Hutton Jason Kolbert 47% 1-year accuracy 15 / 32 met price target | 995%upside $6 | Buy Maintained | 19 Aug 2024 |
EF Hutton Jason Kolbert 47% 1-year accuracy 15 / 32 met price target | 995%upside $6 | Buy Maintained | 8 Aug 2024 |
EF Hutton Jason Kolbert 47% 1-year accuracy 15 / 32 met price target | 995%upside $6 | Buy Maintained | 5 Aug 2024 |
EF Hutton Jason Kolbert 47% 1-year accuracy 15 / 32 met price target | 995%upside $6 | Buy Initiated | 15 Jul 2024 |